Cancer survival linked to cardiovascular hormone/peptide levels
the ONA take:
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in patients with cancer are linked to shorter survival, according to research published online in Heart.
In this study, researchers sought to determine whether the cancer itself affects levels of cardiovascular hormones/peptides.
The researchers assessed circulating levels of several cardiovascular hormones; proteins indicative of inflammation; and high sensitive troponin (hsTNT), a chemical that regulates heart muscle contractions, in 555 people with a first cancer diagnosis.
None of the participants had yet undergone any drug or radiotherapy treatments that might have damaged their heart tissue. The participants were tracked for an average of 25 months.
Almost one-third of the participants died during the monitoring period. Analysis of their blood samples showed that all the hormones measured and hsTNT increased in tandem with disease severity, sometimes to levels 100 times higher than expected.
The researchers report that their findings suggest that these biomarkers were indicative of heart damage not yet clinically evident, but directly linked to the cancer progression.
Furthermore, the findings suggest that the benefits of heart failure drugs for cancer patients may extend beyond helping to reduce cardiovascular side effects of cancer treatment.
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in cancer are linked to shorter survival.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|